Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 2
2016 5
2017 5
2018 2
2019 2
2020 2
2021 2
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

17 results
Results by year
Filters applied: . Clear all
Page 1
Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.
Del Poeta G, Postorino M, Pupo L, Del Principe MI, Dal Bo M, Bittolo T, Buccisano F, Mariotti B, Iannella E, Maurillo L, Venditti A, Gattei V, de Fabritiis P, Cantonetti M, Amadori S. Del Poeta G, et al. Among authors: bittolo t. Drugs Today (Barc). 2016 Apr;52(4):249-60. doi: 10.1358/dot.2016.52.4.2470954. Drugs Today (Barc). 2016. PMID: 27252989 Review.
<i>SF3B1</i>-mutated chronic lymphocytic leukemia shows evidence of NOTCH1 pathway activation including CD20 downregulation.
Pozzo F, Bittolo T, Tissino E, Vit F, Vendramini E, Laurenti L, D'Arena G, Olivieri J, Pozzato G, Zaja F, Chiarenza A, Di Raimondo F, Zucchetto A, Bomben R, Rossi FM, Del Poeta G, Dal Bo M, Gattei V. Pozzo F, et al. Among authors: bittolo t. Haematologica. 2021 Dec 1;106(12):3125-3135. doi: 10.3324/haematol.2020.261891. Haematologica. 2021. PMID: 33121237 Free PMC article.
TP53 Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia.
Bomben R, Rossi FM, Vit F, Bittolo T, D'Agaro T, Zucchetto A, Tissino E, Pozzo F, Vendramini E, Degan M, Zaina E, Cattarossi I, Varaschin P, Nanni P, Berton M, Braida A, Polesel J, Cohen JA, Santinelli E, Biagi A, Gentile M, Morabito F, Fronza G, Pozzato G, D'Arena G, Olivieri J, Bulian P, Pepper C, Hockaday A, Schuh A, Hillmen P, Rossi D, Chiarenza A, Zaja F, Di Raimondo F, Del Poeta G, Gattei V. Bomben R, et al. Among authors: bittolo t. Clin Cancer Res. 2021 Oct 15;27(20):5566-5575. doi: 10.1158/1078-0432.CCR-21-0701. Epub 2021 Jul 20. Clin Cancer Res. 2021. PMID: 34285062
CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression.
Tissino E, Pozzo F, Benedetti D, Caldana C, Bittolo T, Rossi FM, Bomben R, Nanni P, Chivilò H, Cattarossi I, Zaina E, Norris K, Polesel J, Gentile M, Tripepi G, Moia R, Santinelli E, Innocenti I, Olivieri J, D'Arena G, Laurenti L, Zaja F, Pozzato G, Chiarenza A, Di Raimondo F, Rossi D, Pepper C, Hartmann TN, Gaidano G, Del Poeta G, Gattei V, Zucchetto A. Tissino E, et al. Among authors: bittolo t. Blood. 2020 Apr 9;135(15):1244-1254. doi: 10.1182/blood.2019003179. Blood. 2020. PMID: 32006000 Free PMC article.
A B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines.
D'Agaro T, Zucchetto A, Vit F, Bittolo T, Tissino E, Rossi FM, Degan M, Zaja F, Bulian P, Bo MD, Ferrero S, Ladetto M, Zamò A, Gattei V, Bomben R. D'Agaro T, et al. Among authors: bittolo t. Haematologica. 2019 Sep;104(9):e410-e414. doi: 10.3324/haematol.2018.212811. Epub 2019 Feb 28. Haematologica. 2019. PMID: 30819916 Free PMC article. No abstract available.
NOTCH1 mutational status in chronic lymphocytic leukaemia: clinical relevance of subclonal mutations and mutation types.
D'Agaro T, Bittolo T, Bravin V, Dal Bo M, Pozzo F, Bulian P, Rossi FM, Zucchetto A, Degan M, D'Arena G, Chiarenza A, Zaja F, Pozzato G, Di Raimondo F, Rossi D, Gaidano G, Del Poeta G, Gattei V, Bomben R. D'Agaro T, et al. Among authors: bittolo t. Br J Haematol. 2018 Aug;182(4):597-602. doi: 10.1111/bjh.14843. Epub 2017 Jul 12. Br J Haematol. 2018. PMID: 28699643 No abstract available.
Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia.
Del Principe MI, Dal Bo M, Bittolo T, Buccisano F, Rossi FM, Zucchetto A, Rossi D, Bomben R, Maurillo L, Cefalo M, De Santis G, Venditti A, Gaidano G, Amadori S, de Fabritiis P, Gattei V, Del Poeta G. Del Principe MI, et al. Among authors: bittolo t. Haematologica. 2016 Jan;101(1):77-85. doi: 10.3324/haematol.2015.131854. Epub 2015 Nov 12. Haematologica. 2016. PMID: 26565002 Free PMC article.
IGLV3-21*01 is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signaling.
Maity PC, Bilal M, Koning MT, Young M, van Bergen CAM, Renna V, Nicolò A, Datta M, Gentner-Göbel E, Barendse RS, Somers SF, de Groen RAL, Vermaat JSP, Steinbrecher D, Schneider C, Tausch E, Bittolo T, Bomben R, Mazzarello AN, Del Poeta G, Kroes WGM, van Wezel JT, Imkeller K, Busse CE, Degano M, Bakchoul T, Schulz AR, Mei H, Ghia P, Kotta K, Stamatopoulos K, Wardemann H, Zucchetto A, Chiorazzi N, Gattei V, Stilgenbauer S, Veelken H, Jumaa H. Maity PC, et al. Among authors: bittolo t. Proc Natl Acad Sci U S A. 2020 Feb 25;117(8):4320-4327. doi: 10.1073/pnas.1913810117. Epub 2020 Feb 11. Proc Natl Acad Sci U S A. 2020. PMID: 32047037 Free PMC article.
KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival.
Vendramini E, Bomben R, Pozzo F, Benedetti D, Bittolo T, Rossi FM, Dal Bo M, Rabe KG, Pozzato G, Zaja F, Chiarenza A, Di Raimondo F, Braggio E, Parikh SA, Kay NE, Shanafelt TD, Del Poeta G, Gattei V, Zucchetto A. Vendramini E, et al. Among authors: bittolo t. Leukemia. 2019 Aug;33(8):2111-2115. doi: 10.1038/s41375-019-0444-6. Epub 2019 Mar 14. Leukemia. 2019. PMID: 30872781 Free PMC article. No abstract available.
Mutational status of IGHV is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia.
Bulian P, Bomben R, Bo MD, Zucchetto A, Rossi FM, Degan M, Pozzo F, Bittolo T, Bravin V, D'Agaro T, Cerri M, Chiarenza A, Chaffee KG, Condoluci A, D'Arena G, Spina M, Zaja F, Pozzato G, Di Raimondo F, Rossi D, Poeta GD, Gaidano G, Shanafelt TD, Gattei V. Bulian P, et al. Among authors: bittolo t. Haematologica. 2017 Nov;102(11):e443-e446. doi: 10.3324/haematol.2017.170340. Epub 2017 Jul 27. Haematologica. 2017. PMID: 28751560 Free PMC article. No abstract available.
17 results